Viral Conjunctivitis - Pipeline Review, H1 2016

Date: March 16, 2016
Pages: 43
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V5BC2C93C86EN
Leaflet:

Download PDF Leaflet

Viral Conjunctivitis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Viral Conjunctivitis - Pipeline Review, H1 2016’, provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
  • The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects
  • The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Viral Conjunctivitis - Overview
Viral Conjunctivitis - Therapeutics under Development by Companies
Viral Conjunctivitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Viral Conjunctivitis - Products under Development by Companies
Viral Conjunctivitis - Companies Involved in Therapeutics Development
Adenovir Pharma AB
NanoViricides, Inc.
Panoptes Pharma Ges.m.b.H.
Shire Plc
Starpharma Holdings Limited
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
APD-209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EKCCide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-640 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trisialic acid second generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viral Conjunctivitis - Recent Pipeline Updates
Viral Conjunctivitis - Dormant Projects
Viral Conjunctivitis - Discontinued Products
Viral Conjunctivitis - Product Development Milestones
Featured News & Press Releases
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Viral Conjunctivitis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H1 2016
Viral Conjunctivitis - Pipeline by NanoViricides, Inc., H1 2016
Viral Conjunctivitis - Pipeline by Panoptes Pharma Ges.m.b.H., H1 2016
Viral Conjunctivitis - Pipeline by Shire Plc, H1 2016
Viral Conjunctivitis - Pipeline by Starpharma Holdings Limited, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Viral Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2016
Viral Conjunctivitis - Dormant Projects, H1 2016
Viral Conjunctivitis - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Viral Conjunctivitis, H1 2016
Number of Products under Development by Companies, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
Skip to top


Ask Your Question

Viral Conjunctivitis - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: